Product Description
Mechanisms of Action: M3 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Nasal,Oral,Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Chile | Colombia | Dominican Republic | Germany | India | Jordan | Pakistan | South Africa | Sweden | Taiwan | United Kingdom | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Hadassah Medical Organization
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Stroke
Phase 1: Type 1 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
STUDY00002251 | N/A |
Recruiting |
Low Back Pain|Pain, Postoperative |
2026-12-01 |
|
ChiCTR2400084109 | N/A |
Not yet recruiting |
Gingivitis |
2026-06-06 |
|
STUDY00019465 | N/A |
Enrolling by invitation |
Inflammation|Pain, Postoperative|Surgical Wound Infection |
2025-12-31 |
|
NCT03674151 | N/A |
Recruiting |
Burns Unspecified |
2025-12-01 |